NCT04397003 — Washington University School of Medicine neoantigen vaccine trial
Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung Cancer
Registry record
| Registry ID | NCT04397003 ↗ |
|---|---|
| Lead sponsor | Washington University School of Medicine |
| Collaborators | AstraZeneca, Gateway for Cancer Research |
| Phase | Phase 2 |
| Status | Active Not Recruiting |
| Indication | Extensive-stage Small Cell Lung Cancer |
| Enrollment | 6 participants (target) |
| Start date | 2022-03-30 |
| Primary completion | 2027-09-30 (est.) |
| Last registry update | 23 Oct 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT04397003), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
Daily coverage of the modality, tumor type and players this study touches:
Related trials
FAQ
What phase is NCT04397003?
NCT04397003 (Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung Cancer) is registered on ClinicalTrials.gov as Phase 2, sponsored by Washington University School of Medicine.
Is NCT04397003 recruiting?
As of the 2026-10-23 registry update, NCT04397003 is listed as "Active Not Recruiting". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT04397003?
The lead sponsor is Washington University School of Medicine. Collaborators: AstraZeneca, Gateway for Cancer Research.
What condition does NCT04397003 study?
The registered condition is Extensive-stage Small Cell Lung Cancer. Primary completion is listed as 2027-09-30 (estimated).
Are results available for NCT04397003?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT04397003.
Back to the full neoantigen vaccine trial tracker — 106 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.